Search

Satralizumab

[L15536] Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central nervous system (CNS) involving demyelinating lesions … This novel mechanism effectively increases the duration of action of satralizumab, as it allows for single drug molecules to interact with multiple endogenous IL-6 receptors prior to elimination.

Mersalyl

The sodium salt of a mercury-containing derivative of salicylamide, was formerly used (often in combination with theophylline) to treat edema, due to its powerful diuretic properties [L1577]. … Mersalyl is the sodium salt form of mersalyl acid, a mercurial diuretic. It is an outdated drug, and its approval has been discontinued by the FDA.

Meticrane

Meticrane is a diuretic medication. It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].

Ketazolam

Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.

M0002

It is a vasopressin 2 antagonist and represents a new class of compounds – aquaretics – that produce profound diuresis without loss of electrolytes. … It will be of major benefit to those patients not responding satisfactorily to diuretics alone.

Trilostane

Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.

Morphine glucuronide

Niflumic acid

Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

Talniflumate

Talniflumate, is an anti-inflammatory molecule studied and used as a mucin regulator in the treatment of cystic fibrosis, chronic obstructive pulmonary disease (COPD) and asthma [L1400]. … Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this

Revakinagene taroretcel

[A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2. … Revakinagene taroretcel is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF).